The Italian pharmaceutical industry continues to grow and in 2018 it is preparing to surpass German production rates of pharmaceutical products.
According to data recently released by Farmindustria, it has seen 3% production growth, 12% increase in export and 2.3% growth in terms of employment. In Europe, the cornerstone of global pharmaceutical production together with the US and Japan, Italy accounts for 26% in terms of production and 19% for what concerns the market.
Farmindustria states that the Italian pharmaceutical production has reached up to €30 billion, 44 when considering other related industries, with €2.7 billion invested in production, research and development, for activities with a high level of innovation. From 2010 to 2017, industrial production grew by 13%, exports by 52%, the productivity index by 19%.
A trade show like Pharmintech in Italy, is a perfect opportunity to give visibility to the life sciences sector and to its production excellence, representing the best of process technologies, packaging, laboratory instruments, packaging, components and the best digital and automation solutions applied to the sector, from the IoT to data governance.
As life expectancy increases, a higher incidence of autoimmune diseases, intolerances and cancers are emerging, requiring more and more personalised drugs. The dialogue between genomics and big data, between pharma and IT makes it possible to produce these drugs in a sustainable way. The "Pharma 4.0" revolution is tasked with realising what was not possible before.
New technologies such as IoT, cybernetics, augmented and virtual reality, require the management of huge amounts of data, through the interaction between new information systems on one side and machines, equipment, instruments and medical devices on the other, calling companies to think about new business models.
AFI – the Italian Pharmaceutical Industry Association - has recently conducted a survey involving 200 professionals and companies in the pharmaceutical sector, to evaluate the development of a corporate attitude taking advantage of the opportunities generated by a new approach to data governance and its brand-new production.
The scenario emerging from this survey shows how it is necessary to continue investing in this area to maintain the levels of development and growth of the sector, as well as the leadership reached at an international level in recent years.
The lack of adequate data governance, according to Pharmintech however, risks compromising the qualitative level of drugs production and distribution, and consequently can constitute a threat to the Italian pharmaceutical industry.
Pharmintech wants to anticipate this threat, trying to create greater awareness on the part of the management of large pharmaceutical groups, which are investing in technologies for adequate management and data security.
During the exhibition, these issues will be discussed with specific seminars and round tables, while the most advanced technological solutions for adapting the industry to the ongoing revolution will be exhibited by companies representing the international excellence of the pharmacy system.
